about
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheuma...
Read More
105.95
2.52
(2.44%)
2.1M
XNAS Volume
XNAS 14 Jan, 2026 4:30 PM (EST)
High Financial Strength
Affordable Valuation
Technically Bullish
Strong Performer
These stock companies have strong financials and are affordably priced. They also score high in quality and technical metrics which make them popular with investors
View Similar
Embed DVM
Incyte Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..